UV light killing efficacy of fluorescent protein‐expressing cancer cells in vitro and in vivo |
| |
Authors: | Hiroaki Kimura Claudia Lee Katsuhiro Hayashi Kensuke Yamauchi Norio Yamamoto Hiroyuki Tsuchiya Katsuro Tomita Michael Bouvet Robert M Hoffman |
| |
Institution: | 1. AntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111;2. Department of Surgery, University of California, San Diego, 200 West Arbor Drive, San Diego, California 92103‐8220;3. Department of Orthopaedic Surgery, School of Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan;4. UVP, LLC, 2066 West 11th Street, Upland, California 91786 |
| |
Abstract: | We investigated the cell‐killing efficacy of UV light on cancer cells expressing GFP in the nucleus and RFP in the cytoplasm (dual‐color cells). After exposure to various doses of UVA, UVB, or UVC, apoptotic and viable cells were quantitated under fluorescence microscopy using dual‐color 143B human osteosarcoma cells, HT‐1080 human fibrosarcoma cells, Lewis lung carcinoma (LLC), and XPA‐1 human pancreatic cancer cells in vitro. UV‐induced cancer cell death was wave‐length and dose dependent, as well as cell‐line dependent. After UVA exposure, most cells were viable even when the UV dose was increased up to 200 J/m2. With UVB irradiation, cell death was observed with irradiation at 50 J/m2. For UVC, as little as 25 J/m2 UVC irradiation killed approximately 70% of the 143B dual‐color cells. This dose of UVB or UVA had almost no effect on the cancer cells. UV‐induced cancer cell death varied among the cell lines. Cell death began about 4 h after irradiation and continued until 10 h after irradiation. UVC exposure also suppressed cancer cell growth in nude mice in a model of minimal residual cancer (MRC). No apparent side effects of UVC exposure were observed. This study opens up the possibility of UVC treatment for MRC after surgical resection. J. Cell. Biochem. 110: 1439–1446, 2010. © 2010 Wiley‐Liss, Inc. |
| |
Keywords: | UVC GFP RFP fluorescence imaging real‐time cellular imaging in vitro in vivo minimal residual cancer |
|
|